Annexon Maps “Pivotal” 2026 at JPM Conference: ANX007 Phase 3 GA Readout, ANX005 Filings Ahead

Annexon (NASDAQ:ANNX) used its presentation at the 44th Annual J.P. Morgan Healthcare Conference to outline a set of ...
Seeking Alpha

Speculative "Buy" Rating On Annexon: Evaluating The Potential Of ANX005 For GBS

Annexon’s ANX005 shows promise for GBS. Phase 3 trial results indicate expedited recovery and durable benefits. ANNX targets the classical complement pathway, specifically the C1q protein, to address ...
Morningstar

Annexon Reports Phase 1 Results for ANX1502, its Oral Small Molecule Inhibitor of the Classical Complement Pathway

About Annexon Annexon Biosciences (Nasdaq: ANNX) is a clinical-stage biopharmaceutical company utilizing a distinct scientific approach to stop C1q and all inflammatory aspects of classical complement ...
Nasdaq

Annexon Reports Phase 1 Results for ANX1502, its Oral Small Molecule Inhibitor of the Classical Complement Pathway

Target Levels of Active Drug Achieved in Healthy Volunteers with Oral Twice-Daily Dosing; Supportive Impact on Pharmacodynamic Biomarker of Complement Activity ANX1502 Generally Well Tolerated Across ...